Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up.

摘要: A retrospective analysis of the initial 229 cases disseminated germ cell tumors treated at Indiana University with cisplatin, vinblastine, and bleomycin (PVB), or without doxorubicin revealed 146 patients who are alive disease-free a minimum follow-up 6 years median 8.5 years. At 12 years, estimated probability survival is 65.0%, relapse-free for complete responders 83.5%. Long-term complications, such as clinically significant organ toxicity therapy-related second malignancies, have not been observed. The functional status survivors maintained, 95% returning to their pretherapy status, which 88% fully employed. Of receiving chemotherapy abdominal surgery, 35% fathered healthy children posttherapy. Achievement remission (CR) in cisplatin-based combination translates long-term cure t...